文献速递浆细胞疾病

低循环肿瘤细胞水平与多发性骨髓瘤良好结局及独特生物学特征相关

Low circulating tumor cell levels correlate with favorable outcomes and distinct biological features in multiple myeloma.
PubMed 文献 · Am J Hematol · 2024-06-11

该研究在550例新诊断多发性骨髓瘤患者的骨髓和外周血配对样本中应用二代流式细胞术,确定适合移植与不适合移植患者的最佳循环肿瘤细胞(CTC)截断值,发现0.02% CTC截断值独立于ISS、LDH和细胞遗传学,低CTC水平与良好生存及独特微环境特征相关。

要点

  • 90%患者可检测到CTC(中位0.01%,范围0.0002%-12.6%),高水平CTC与不良特征相关。
  • CTC每增加一个对数级,无进展生存(PFS)和总生存(OS)逐渐恶化。
  • 0.02% CTC截断值在多因素分析中独立于ISS、LDH和细胞遗传学预测PFS。

核心结论

  • 该研究显示CTC评估在多发性骨髓瘤中具有临床实用性,并为风险分层的共识截断值提供了证据。

研究设计与样本

  • 研究应用二代流式细胞术检测550例新诊断多发性骨髓瘤患者的骨髓和外周血配对样本,涵盖适合移植和不适合移植患者。

主要发现

  • 90%患者检测到CTC,中位0.01%,范围0.0002%-12.6%;高水平CTC与不良特征相关。
  • 高CTC百分比与弥漫性MRI模式、独特骨髓组成(B细胞分化改变伴效应细胞和肿瘤相关巨噬细胞扩增)及骨髓与外周血克隆细胞表型差异更大相关。
  • PFS和OS随CTC每增加一个对数级逐渐恶化。
  • 无CTC的新诊断患者5年PFS率和OS率分别为83%和97%。
  • 0.02% CTC截断值在多因素分析中独立于ISS、LDH和细胞遗传学预测PFS。

关键数值与推荐

  • CTC中位0.01%,范围0.0002%-12.6%,在90%患者中检测到。
  • 无CTC患者5年PFS率83%,5年OS率97%。
  • CTC截断值0.02%在多因素分析中独立于ISS、LDH和细胞遗传学预测PFS。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There is growing interest in multiple myeloma (MM) circulating tumor cells (CTCs), but their rareness in peripheral blood (PB) and inconsistency in cutoffs question their clinical utility. Herein, we applied next-generation flow cytometry in 550 bone marrow (BM) and matched PB samples to define an optimal CTC cutoff for both transplant-eligible and transplant-ineligible newly diagnosed MM (NDMM) patients. Deep phenotyping was performed to investigate unique microenvironmental features associated with CTC dissemination. CTCs were detected in 90% of patients (median 0.01%; range: 0.0002%-12.6%) and increased levels associated with adverse features. Correlations were observed between high CTC percentages and a diffused MRI pattern, a distinct BM composition characterized by altered B-cell differentiation together with an expansion of effector cells and tumor-associated macrophages, as well as a greater phenotypic dissimilarity between BM and PB clonal cells. Progression-free survival (PFS) and overall survival (OS) gradually worsened with each logarithmic increment of CTCs. Conversely, NDMM patients without CTCs showed unprecedented outcomes, with 5-year PFS and OS rates of 83% and 97%, respectively. A cutoff of 0.02% CTCs was independent of the ISS, LDH, and cytogenetics in a multivariate analysis of risk factors for PFS. The 0.02% CTC cutoff synergized with the MGUS-like phenotype and the R-ISS for improving the risk stratification systems. MRD negativity was less frequent if CTCs were ≥0.02% at diagnosis, but whenever achieved, the poor prognosis of these patients was abrogated. This study shows the clinical utility of CTC assessment in MM and provides evidence toward a consensus cutoff for risk stratification.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Kostopoulos IV, Ntanasis-Stathopoulos I, Rousakis P, et al. Low circulating tumor cell levels correlate with favorable outcomes and distinct biological features in multiple myeloma. Am J Hematol. 2024. PMID: 38860642. doi:10.1002/ajh.27414

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。